Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Olga Gumkowska-SrokaDepartment of Internal Medicine Rheumatology and Clinical Immunology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-635 Katowice, Poland.
Anna ChudekHealth Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland.ORCID 0000-0002-6140-4602
Aleksander OwczarekHealth Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland.
Kornelia Kuźnik-TrochaDepartment of Clinical Chemistry and Laboratory Diagnostics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 41-200 Katowice, Poland.ORCID 0000-0003-4762-4841
Kacper KotylaDepartment of Internal Medicine Rheumatology and Clinical Immunology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-635 Katowice, Poland.
Jan KurdybachaDepartment of Internal Medicine Rheumatology and Clinical Immunology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-635 Katowice, Poland.
Jerzy ChudekDepartment of Internal Medicine and Oncological Chemotherapy, Medical University of Silesia, 40-029 Katowice, Poland.ORCID 0000-0002-6367-7794
Katarzyna Komosińska-VassevDepartment of Clinical Chemistry and Laboratory Diagnostics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 41-200 Katowice, Poland.ORCID 0000-0003-2307-5884
Katarzyna Winsz-SzczotkaDepartment of Clinical Chemistry and Laboratory Diagnostics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 41-200 Katowice, Poland.ORCID 0000-0003-3574-4133
Krystyna OlczykDepartment of Clinical Chemistry and Laboratory Diagnostics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 41-200 Katowice, Poland.ORCID 0000-0002-5833-2628
Przemysław KotylaDepartment of Internal Medicine Rheumatology and Clinical Immunology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-635 Katowice, Poland.ORCID 0000-0001-8376-6527
Funding
Medical University of Silesia, Katowice, Poland KNW-1-172/N/8/K
6 · The paper itself
Abstract
Systemic sclerosis, a connective tissue disease of unknown etiology and unpredictable outcomes, is characterized by the fibrosis of the skin and internal organs, vasculopathy, and immune system dysregulation. The disease is classified into two main subtypes, which differ in clinical presentation, complications, and prognosis. While several biomarkers have been proposed to distinguish between these subtypes, none have achieved high sensitivity and specificity. The search for dependable markers that can differentiate between the two primary subtypes of systemic sclerosis continues. To address this gap, our study evaluated the utility of novel cardiac biomarkers, including growth differentiation factor 15 (GDF15), galectin-3, mid-regional pro-atrial natriuretic peptide (MR-proANP), glutathione S-transferase π, mid-regional adrenomedullin, and soluble urokinase plasminogen activator receptor (suPAR), in a cohort of 79 patients with both lcSSc and dSSc subtypes. The results demonstrated a significant elevation of GDF15 (medians: 2.07 vs. 1.10 ng/L;
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Potential of Cardiac Biomarkers in Differentiating Disease Subtypes in Patients with Systemic Sclerosis: Focus on GDF15, MR-pro ANP, and suPAR. · full record | OpenQuestion